Cognition Therapeutics, Inc. CGTX
0.68 USD 0.00 (+0.52%)
At closeNov 13, 2026, 5:36 PM EST
0.70 +0.02 +2.97%
After hours · Nov 13, 5:36 PM ET
0.6505 Day range 0.6999
0.55 52-week range 1.81
- YTD
- -49.64%
- 1 year
- -55.86%
News
zacks.com What Makes Cognition Therapeutics (CGTX) a New Buy Stock Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference PURCHASE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the…
seekingalpha.com Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript
marketbeat.com Cognition Therapeutics Q3 Earnings Call Highlights Cognition Therapeutics NASDAQ: CGTX is preparing a Phase III trial of its experimental drug zervimesine in dementia with Lewy bodies after reaching alignment with the U.S. Food and Drug…
benzinga.com Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 33.33 percent increase over losses…
globenewswire.com Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the…
globenewswire.com Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 -- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product…
benzinga.com Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints The planned registrational study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine…
globenewswire.com Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat…
benzinga.com Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine The patent has a natural expiration of 2045. Upon zervimesine’s approval by the U.S. Food and Drug Administration (FDA), the patent may be eligible for an extension of up to five additional years.The…
globenewswire.com Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 - An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
benzinga.com Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"),
globenewswire.com Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
globenewswire.com Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
zacks.com Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates Cognition Therapeutics, Inc. (CGTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.11 per share a year ago.
benzinga.com Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses…
globenewswire.com Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the…
globenewswire.com Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
seekingalpha.com Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…- benzinga.com FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it…
globenewswire.com Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -
benzinga.com Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has…
globenewswire.com Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative…
globenewswire.com Cognition Therapeutics Participating in Upcoming Investor Conferences PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
globenewswire.com Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a…- benzinga.com Cognition Therapeutics Announces Second Philanthropic Donation From A Participant In The Ongoing Expanded Access Program For People With Dementia With Lewy Bodies The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach,…
globenewswire.com Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative…- benzinga.com Cognition Therapeutics To Update On Progress Of Its Development Programs For Alzheimer's Disease And Dementia With Lewy Bodies At 25th Annual Needham Virtual Healthcare Conference Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of…
benzinga.com Earnings Scheduled For March 26, 2026 
benzinga.com Cognition Therapeutics Presents Analysis From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2…- benzinga.com Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the…
- benzinga.com Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food…
- benzinga.com Cognition Therapeutics Study On Phase 2 Trial Of Zervimesine In Patients With Mild-to-Moderate Dementia With Lewy Bodies Meets Primary Endpoint Of Safety, Tolerability Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, "Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)"…
benzinga.com Cognition Therapeutics Files Prospectus To Offer Up To $300M In Securities Common StockPreferred StockDebt SecuritiesWarrantsUnitsSubscription RightsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or…- benzinga.com HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
benzinga.com Cognition Therapeutics Reaches Full Patients Enrollment For Zervimesine In Dementia Trial Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access…- benzinga.com Cognition Therapeutics Presented Plans For Registrational Program For Zervimesine In Mild-To-Moderate Alzheimer's Disease Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program…
- benzinga.com B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3 B. Riley Securities analyst William Woods reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and raises the price target from $2 to $3.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
- benzinga.com Cognition Therapeutics Reaches Target Enrollment Of 540 Patients In Phase 2 START Trial To Evaluate Zervimesine To Treat Early Alzheimer's Disease Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target…
- benzinga.com Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 76 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Reported Earlier: Cognition Therapeutics Reports Zervimesine (CT1812) Results In Phase 2 SHIMMER DLB, SHINE Alzheimer's & MAGNIFY Dry AMD Studies; Moving Toward Phase 3 Trials https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_ex99-1.htm- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - benzinga.com Reported Earlier, Cognition Therapeutics Secures $30M From Registered Direct Offering Made To Two Fundamental Institutional Investors - The offering was made to two new fundamental institutional investors -- The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative…